# US 2010/0166824 A1 · Extracellular matrix compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166824 A1
- Document ID: US20100166824A1
- Status: Published application
- Kind: A1
- Application number: 12/501,312
- Filed: 2009-07-10
- Published: 2010-07-01
- Earliest claimed: 2008-01-30
- Assignees: Histogen, Inc.
- Inventors: Gail K. Naughton; Frank Ziegler; Mark Baumgartner; Kyle Nickey
- Web page: https://patentgrep.com/patent/US20100166824A1

## CPC

- A61L 27/3895: {using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions}
- A61K 35/33: Fibroblasts
- A61K 35/54: Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K 38/18: Growth factors; Growth regulators
- A61K 38/1866: {Vascular endothelial growth factor [VEGF]}
- A61K 38/39: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A61L 27/34: Macromolecular materials
- A61L 29/085: {Macromolecular materials}
- A61L 31/10: Macromolecular materials
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 19/04: for non-specific disorders of the connective tissue
- C12N 5/0068: {General culture methods using substrates (for specific animal cell type C12N5/06)}
- C12N 5/0627: {Hair cells}
- C12N 5/0656: {Adult fibroblasts}
- C12N 2500/02: Atmosphere, e.g. low oxygen conditions
- C12N 2500/90: Serum-free medium, which may still contain naturally-sourced components
- C12N 2501/165: Vascular endothelial growth factor [VEGF]
- C12N 2501/415: Wnt; Frizzeled
- C12N 2533/54: Collagen; Gelatin
- C12N 2533/90: Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention is directed to a method of producing compositions including embryonic proteins. The method includes culturing cells under hypoxic conditions on a biocompatible three-dimensional surface in vitro. The culturing method produces both soluble and non-soluble fractions, which may be used separately or in combination to obtain physiologically acceptable compositions useful in a variety of medical and therapeutic applications.

## Claims

### Claim 1

A method of making a composition comprising one or more embryonic proteins comprising:
culturing cells under hypoxic conditions on a surface in a suitable growth medium, thereby producing a soluble and a non-soluble composition comprising one or more embryonic proteins.

### Claim 2 (depends on 1)

The method of claim 1, wherein the growth medium comprises serum.

### Claim 3 (depends on 1)

The method of claim 1, wherein the growth medium is serum-free.

### Claim 4 (depends on 1)

The method of claim 1, wherein the hypoxic oxygen conditions are 1-5% oxygen.

### Claim 5 (depends on 1)

The method of claim 1, wherein collagen species are upregulated as compared with media produced in oxygen conditions of about 15-20% oxygen.

### Claim 6 (depends on 5)

The method of claim 5, wherein the collagen is selected from type V alpha 1; IX alpha 1; IX alpha 2; VI alpha 2; VIII alpha 1; IV, alpha 5; VII alpha 1; XVIII alpha 1; or XII alpha 1.

### Claim 7 (depends on 1)

The method of claim 1, wherein Wnt species are upregulated as compared with media produced in oxygen conditions of about 15-20% oxygen.

### Claim 8 (depends on 7)

The method of claim 7, wherein the Wnt species are wnt 7a and wnt 11.

### Claim 9 (depends on 1)

The method of claim 1, wherein laminin species are upregulated as compared with media produced in oxygen conditions of about 15-20% oxygen.

### Claim 10 (depends on 9)

The method of claim 9, wherein the laminin species is laminin 8.

### Claim 11 (depends on 1)

The method of claim 1, wherein the cell-free supernatant is dialyzed, lyophilized and reconstituted in a buffer.

### Claim 12 (depends on 1)

The method of claim 1, wherein the cell-free supernatant is dialyzed, desiccated and reconstituted in a buffer.

### Claim 13 (depends on 1)

The method of claim 1, wherein the cells are fibroblasts.

### Claim 14 (depends on 13)

The method of claim 13, wherein the fibroblasts are neonatal fibroblasts.

### Claim 15 (depends on 1)

The method of claim 1, wherein the surface is three-dimensional.

### Claim 16 (depends on 15)

The method of claim 15, wherein the surface comprises mesh.

### Claim 17 (depends on 1)

The method of claim 1, wherein the surface is two-dimensional.

### Claim 18 (depends on 17)

The method of claim 17, wherein the surface comprises beads.

### Claim 19 (depends on 1)

The method of claim 1, wherein the cells are species specific.

### Claim 20 (depends on 1)

A composition prepared by the method of claim 1, wherein the composition is the soluble fraction.

### Claim 21 (depends on 1)

A composition prepared by the method of claim 1, wherein the composition is the non-soluble fraction.

### Claim 22 (depends on 1)

A composition prepared by the method of claim 1, wherein the composition is a combination of the soluble and non-soluble fraction.

### Claim 23 (depends on 20, 21, 22)

A method of repair and/or regeneration of cells comprising contacting cells to be repaired or regenerated with the composition of any of claim 20, 21 or 22.

### Claim 24 (depends on 23)

The method of claim 23, wherein the cells are osteochondral cells.

### Claim 25 (depends on 20, 21, 22)

A tissue regeneration patch comprising a composition of any of claim 20, 21 or 22.

### Claim 26 (depends on 20, 21, 22)

A tissue culture system including a composition as in any of claim 20, 21 or 22.

### Claim 27 (depends on 26)

The tissue culture system of claim 26, wherein the system is used to support the growth of stem cells.

### Claim 28 (depends on 27)

The tissue culture system of claim 27, wherein the stem cells are embryonic stem cells, mesenchymal stem cells or neuronal stem cells.

### Claim 29 (depends on 20, 21, 22)

A surface coating used in association with implantation of a device in a subject comprising a composition of any of claim 20, 21 or 22.

### Claim 30 (depends on 29)

The coating of claim 29, wherein the device is a pacemaker, a stent, a stent graft, a vascular prosthesis, a heart valve, a shunt, a drug delivery port, a catheter, or a patch.

### Claim 31 (depends on 29)

The coating of claim 29, wherein the coating is used for modifying wound healing, modifying inflammation, modifying a fibrous capsule formation, modifying tissue ingrowth, or modifying cell ingrowth.

### Claim 32 (depends on 20, 21, 22)

A method of treating damaged tissue comprising contacting the damaged tissue with a composition as in any of claim 20, 21 or 22 under conditions that allow for treatment of the damaged tissue.

### Claim 33 (depends on 32)

The method of claim 32, wherein the tissue is heart tissue.

### Claim 34 (depends on 32)

The method of claim 32, wherein the tissue is infarcted or ischemic tissue.

### Claim 35 (depends on 32)

The method of claim 32, wherein the tissue is intestinal tissue.

### Claim 36 (depends on 20, 21, 22)

A method for improvement of a skin surface in a subject comprising administering to the subject at the site of a wrinkle, a composition as in any of claim 20, 21 or 22, thereby providing an improved skin surface.

### Claim 37 (depends on 20, 21, 22)

A biological anti-adhesion agent comprising a composition as in any of claim 20, 21 or 22.

### Claim 38 (depends on 20, 21, 22)

A biological vehicle for cell delivery or maintenance at a site of delivery comprising a composition as in any of claim 20, 21 or 22.

### Claim 39 (depends on 20, 21, 22)

A method for soft tissue repair or augmentation in a subject comprising administering to the subject at the site of a wrinkle, a composition as in any of claim 20, 21 or 22, thereby providing soft tissue repair or augmentation.

### Claim 40 (depends on 20, 21, 22)

A method of promoting hair growth comprising contacting a cell with a composition as in any of claim 20, 21 or 22, thereby promoting hair growth.

### Claim 41 (depends on 40)

A method of claim 40, wherein the cell is a hair follicle cell.

### Claim 42 (depends on 40)

The method of claim 40, wherein the cell is contacted in vivo.

### Claim 43 (depends on 40)

The method of claim 40, wherein the cell is contacted ex vivo.

### Claim 44 (depends on 43)

The method of claim 43, wherein the cell is transplanted into a subject.

### Claim 45

A method of producing a Wnt protein and a vascular endothelial growth factor (VEGF) comprising:
culturing cells under hypoxic conditions on a surface in a suitable growth medium, thereby producing the Wnt protein and the VEGF.

### Claim 46 (depends on 45)

The method of claim 45, wherein the growth medium is serum-free.

### Claim 47 (depends on 45)

The method of claim 45, wherein the hypoxic oxygen conditions are 1-5% oxygen.

### Claim 48 (depends on 47)

The method of claim 47, wherein Wnt species are upregulated as compared with media produced in oxygen conditions of about 15-20% oxygen.

### Claim 49 (depends on 48)

The method of claim 48, wherein the Wnt species are wnt 7a and wnt 11.

### Claim 50 (depends on 45)

The method of claim 45, wherein VEGF species are upregulated as compared with media produced in oxygen conditions of about 15-20% oxygen.

### Claim 51 (depends on 50)

The method of claim 50, wherein the VEGF species is VEGF-A or isoform thereof.

### Claim 52 (depends on 45)

The method of claim 45, wherein the cells are fibroblasts.

### Claim 53 (depends on 45)

The method of claim 45, wherein the surface is three-dimensional.

### Claim 54 (depends on 53)

The method of claim 53, wherein the surface comprises mesh.

### Claim 55 (depends on 45)

The method of claim 45, wherein the surface is two-dimensional.

### Claim 56 (depends on 55)

The method of claim 55, wherein the surface comprises beads.
